OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

ModifiedAmbetter NevadaPolicy N/A

Outpatient Respiratory Infectious Disease Diagnostic Testing — Coding & Coverage (Lab)

Customize your policy alerts

Sign up for all Ambetter Nevada policy alerts

Know when Ambetter Nevada releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Governs medical necessity and coding implications for outpatient respiratory pathogen testing (viral and bacterial panels, antigen/antibody tests, and Group A streptococcus testing) for Ambetter Nevada members.

Policy Summary

PayerAmbetter Nevada

PolicyOutpatient respiratory infectious disease diagnostic testing (coverage criteria and coding)

Policy CodePolicy N/A

Change TypeCPT additions/removals and coding table corrections

Effective DateN/A

Next Review DateN/A

Key ActionDocument clinical justification showing outpatient acute respiratory signs/symptoms and that test results will influence management; use updated CPT/HCPCS codes when submitting claims.

SourceLink

POLICY UPDATE CHANGES

Added 0528U as an in-scope CPT code.

Removed deleted codes U0003, U0004, and U0005.

Updated CPT code table — corrected code descriptions and removed code 0373U.

Added 'Lab' to policy title and moved the 'coding implications' section.

6+Syndromic panel threshold

5 or fewerSmaller multiplex threshold

3-18Pediatric culture age range

3Revision notes (code changes)

18/8/7PLA analytes in 0528U

Medical Necessity — Respiratory Infectious Disease Testing

Syndromic/Multiplex Respiratory Panels (6+ targets)

Covered when ALL of the following are met:

Panel general criteria: Member presents in the outpatient setting with signs or symptoms of an acute respiratory infection AND results of the testing will influence the member's/enrollee's clinical management.

Additional qualifying conditions: Member meets at least one of: immunocompromised; severe pneumonia; exacerbations of airway disease.

Smaller multiplex respiratory viral panels (<=5 targets) and individual SARS-CoV-2/Flu/RSV testing

Covered when ALL of the following are met:

Policy Summary

PayerAmbetter Nevada

PolicyOutpatient respiratory infectious disease diagnostic testing (coverage criteria and coding)

Policy CodePolicy N/A

Change TypeCPT additions/removals and coding table corrections

Effective DateN/A

Next Review DateN/A

Key ActionDocument clinical justification showing outpatient acute respiratory signs/symptoms and that test results will influence management; use updated CPT/HCPCS codes when submitting claims.

SourceLink

On This Page

Clinical indications and recommendations (guideline excerpts)

Guideline-based clinical contexts cited (IDSA, CDC, AAFP):

Appropriate uses referenced: Multiplex viral NAATs (>=6 targets) may be clinically sensible for immunocompromised and critically ill patients with pneumonia and for exacerbations of airway disease (IDSA).

source: IDSA guidance

Multiplex or targeted testing for common viruses: Molecular testing for SARS-CoV-2, RSV, or influenza A/B and smaller multiplex panels (<=5 targets) may be appropriate for symptomatic outpatients and during periods of high prevalence (IDSA, CDC).

Bacterial NAAT indications: Bacterial NAATs may be most useful when patients have new or worsening lung infiltrates, are moderately to severely ill, received empiric antibiotics before cultures, or there is concern for multidrug-resistant bacteria or polymicrobial infection (IDSA).

source: IDSA guidance

Serology not recommended for acute influenza: Serologic testing should not be used for routine diagnosis of acute influenza because single serum specimens are not reliably interpretable (IDSA).

source: IDSA 2018

Group A Strep testing guidance: RADT and/or culture recommended for GAS pharyngitis; in children a negative RADT should be backed up by throat culture; routine back-up culture generally not needed for adults (IDSA, AAFP, CDC).

Anti-streptococcal antibody testing: Anti-streptococcal antibody titers are not recommended for routine diagnosis of acute pharyngitis because they indicate past infection and peak weeks after infection (IDSA).

Codes and Test Mapping

Covered CPT/PLA CodesmixedCovered

0202U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including SARS-CoV-2, qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected.
0223U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including SARS-CoV-2, qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected.
0225U	Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including SARS-CoV-2, amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.
0240U	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (SARS-CoV-2, influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected.
0241U	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (SARS-CoV-2, influenza A, influenza B, RSV), upper respiratory specimen, each pathogen reported as detected or not detected.
0528U	Lower respiratory tract infectious agent detection, 18 bacteria, 8 viruses, and 7 antimicrobial-resistance genes, amplified probe technique, including reverse transcription for RNA targets, each analyte reported as detected or not detected with semiquantitative results for 15 bacteria.

Antigen and Multiplex NAAT CPT CodesCPT

87400	Infectious agent antigen detection by immunoassay; Influenza A or B, each.
87420	Infectious agent antigen detection by immunoassay; respiratory syncytial virus.
87426	Infectious agent antigen detection by immunoassay; SARS-CoV-2.
87428	Infectious agent antigen detection by immunoassay; SARS-CoV-2 and influenza A and B.
87631	Infectious agent detection by nucleic acid; respiratory virus, multiplex amplified probe technique, 3-5 targets.
87632	Infectious agent detection by nucleic acid; respiratory virus, multiplex amplified probe technique, 6-11 targets.
87633	Infectious agent detection by nucleic acid; respiratory virus, multiplex amplified probe technique, 12-25 targets.

Antibody and Culture CodesCPT

87116	Culture, tubercle or other acid-fast bacilli, with isolation and presumptive identification of isolates.
87118	Culture, mycobacterial, definitive identification, each isolate.
87140	Culture, typing; immunofluorescent method, each antiserum.
87143	Culture, typing; GLC or HPLC method.
87147	Culture, typing; immunologic method, other than immunofluorescence, per antiserum.
87158	Culture, typing; other methods.
87275	Infectious agent antigen detection by immunofluorescent technique; influenza B virus.
87276	Infectious agent antigen detection by immunofluorescent technique; influenza A virus.

Chlamydia and Mycoplasma Nucleic Acid CodesCPT

87485	Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia pneumoniae, direct probe technique.
87486	Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia pneumoniae, amplified probe technique.
87487	Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia pneumoniae, quantification.
87580	Infectious agent detection by nucleic acid (DNA or RNA); Mycoplasma pneumoniae, direct probe technique.
87581	Infectious agent detection by nucleic acid (DNA or RNA); Mycoplasma pneumoniae, amplified probe technique.
87582	Infectious agent detection by nucleic acid (DNA or RNA); Mycoplasma pneumoniae, quantification.

Other NAAT and Antigen CodesCPT

87500	Vancomycin resistance detection, amplified probe technique.
87501	Influenza virus nucleic acid detection, includes reverse transcription and amplified probe technique, each type or subtype.
87502	Influenza virus nucleic acid detection for multiple types/sub-types, multiplex reverse transcription and amplified probe technique, first 2 types/sub-types.
87503	Influenza virus additional types/sub-types (list separately).
87634	Infectious agent detection by nucleic acid; RSV, amplified probe technique.
87635	Infectious agent detection by nucleic acid; SARS-CoV-2, amplified probe technique.
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza A/B, multiplex amplified probe technique.
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza A/B, and RSV, multiplex amplified probe technique.

Generic/Other Nucleic Acid DetectionCPT

87797	Infectious agent detection by nucleic acid, not otherwise specified; direct probe technique, each organism.
87798	Infectious agent detection by nucleic acid, not otherwise specified; amplified probe technique, each organism.
87799	Infectious agent detection by nucleic acid, not otherwise specified; quantification, each organism.
87800	Infectious agent detection by nucleic acid (DNA or RNA), multiple organisms; direct probe(s) technique.
87801	Infectious agent detection by nucleic acid (DNA or RNA), multiple organisms; amplified probe(s) technique.

Antigen Immunoassay (Point-of-Care) CodesCPTCovered

87804	Infectious agent antigen detection by immunoassay with direct optical observation; Influenza.
87807	Infectious agent antigen detection by immunoassay with direct optical observation; RSV.
87811	Infectious agent antigen detection by immunoassay with direct optical observation; SARS-CoV-2.
87880	Infectious agent antigen detection by immunoassay with direct optical observation; Streptococcus, group A.

Documentation, Billing, and Operational Guidance

Denial Risk

Failure to meet stated criteria

Tests performed outside the stated medical necessity criteria (see policy sections on syndromic/multiplex respiratory panels, SARS‑CoV‑2/RSV/Influenza or ≤5-target panels, bacterial respiratory panels, and Group A streptococcus culture) may be denied. Ensure clinical documentation supports outpatient presentation with signs/symptoms and demonstrates that test results will influence clinical management.

Tests not meeting the listed clinical criteria are at risk for denial.
Document chief complaint, relevant signs/symptoms, and how results will change management (e.g., antimicrobial selection, infection control).

Billing Rule

Risk from obsolete or incorrect codes

Do not rely on legacy or removed CPT/HCPCS codes when ordering or billing. Use the policy's most current CPT code table and confirm codes/descriptions against the latest AMA and payer coding guidance. Using obsolete or incorrect codes can lead to claim denials or delayed reimbursement.

Refer to the updated CPT code table included in this policy at the time of service.
Check for recently deleted PLA/U codes (e.g., removed U0003–U0005, 0373U) and added codes (e.g., 0528U) before claim submission.

Documentation Required

RADT before culture in pediatric patients

For pediatric patients (ages 3–18 years), obtain a negative rapid antigen detection test (RADT) for Group A streptococcus before performing a throat culture, unless strong clinical justification exists to proceed directly to culture. Document the RADT result in the medical record.

Applicable age range: 3–18 years.
RADT must be negative prior to culture for Group A streptococcus per policy criteria.
If culture is performed after a positive RADT or without documented RADT, include rationale in the chart to justify testing.

Note

Coding is informational only

Coding listings in this policy are informational and do not by themselves establish coverage or prior authorization requirements. Providers should reference current professional coding resources and payer-specific instructions prior to claim submission.

Inclusion or exclusion of codes in this document does not guarantee coverage.
Confirm code-to-test mapping with the performing laboratory and payer guidance.

Key Definitions and Clinical Terms

Severe pneumonia — IDSA/ATS definition (major/minor criteria)

DefinitionSevere pneumonia is defined by IDSA/ATS criteria as presence of one major criterion or at least three minor criteria

Major criteria (examples)Septic shock requiring vasopressors; respiratory failure requiring mechanical ventilation

Minor criteria (examples)Respiratory rate >30 breaths/min; PaO2/FiO2 <250; multilobar infiltrates; confusion; BUN >20 mg/dL; WBC <4,000/μl; platelets <100,000/μl; core temp <36°C; hypotension needing aggressive fluids

Moderate to severe upper respiratory illness

DefinitionModerate to severe upper respiratory illness includes one or more clinical findings of lower respiratory illness (e.g., pneumonia, severe cough/bronchitis, shortness of breath, difficulty breathing)

Clinical examplesPneumonia, severe cough or bronchitis, dyspnea or difficulty breathing

Context for testingUsed as qualifying condition for syndromic/multiplex panels and bacterial panels when present

Airway disease — definition and examples

DefinitionAirway disease: nonspecific term for a heterogeneous group of conditions including COPD, emphysema, cystic fibrosis, asthma, and bronchiectasis

ExamplesChronic obstructive pulmonary disease (COPD), emphysema, cystic fibrosis, asthma, bronchiectasis

RelevanceExacerbations of airway disease qualify patients for consideration of syndromic multiplex panels (≥6 targets)

Moderate to severe upper respiratory illness (duplicate entry)

Definition (duplicate)Moderate to severe upper respiratory illness includes one or more clinical findings of lower respiratory illness (e.g., pneumonia, severe cough/bronchitis, shortness of breath)

Use in policyListed as a qualifying condition for bacterial panels and syndromic panels where applicable

Clinical signsShortness of breath, difficulty breathing, severe cough, imaging consistent with pneumonia

Severe pneumonia (duplicate entry)

Definition (duplicate)Severe pneumonia per IDSA/ATS: presence of one major criterion (septic shock needing vasopressors or respiratory failure requiring mechanical ventilation) or ≥3 minor criteria

Major criterion examplesSeptic shock requiring vasopressors; respiratory failure requiring mechanical ventilation

Minor criteria examplesRR >30, PaO2/FiO2 <250, multilobar infiltrates, confusion, BUN >20 mg/dL, WBC <4,000/μl, platelets <100,000/μl, core temp <36°C, hypotension requiring fluids

Airway disease (duplicate entry)

Definition (duplicate)Airway disease: heterogeneous group including COPD, emphysema, cystic fibrosis, asthma, and bronchiectasis

Clinical relevanceExacerbations are an indication for syndromic multiplex testing when criteria are met

ExamplesCOPD, emphysema, cystic fibrosis, asthma, bronchiectasis

Acute respiratory infection — signs and symptoms

DefinitionAcute respiratory infection: signs and symptoms of upper or lower respiratory tract infection (cough, runny nose, sore throat, bronchitis, pneumonia, bronchiolitis), with or without fever

IncludesInfluenza-like illness (fever plus cough or sore throat) and respiratory distress (increased RR, accessory muscle use)

Policy usePresence of acute respiratory infection symptoms is a core requirement for outpatient testing coverage

Multiplex amplified probe — technique

DefinitionMultiplex amplified probe: a nucleic acid detection technique used for multiple targets in a single assay (multiplex RT and amplified probe techniques referenced in CPT descriptors)

CPT contextReferenced in descriptions for CPT codes 87631–87637 indicating technique applicability to panels of varying target counts

Use casesApplied to viral panels detecting multiple respiratory pathogens such as influenza, RSV, adenovirus, rhinovirus, metapneumovirus

Antigen immunoassay (direct optical) — definition

DefinitionAntigen immunoassay (direct optical): infectious agent antigen detection by immunoassay with direct optical (visual) observation

CPT examplesCPTs 87804 (Influenza), 87807 (RSV), 87811 (SARS‑CoV‑2), and 87880 (Group A Strep) are described as direct optical antigen immunoassays

Clinical roleUsed for rapid antigen detection tests (RADT) that may precede culture in pediatric Group A Streptococcus workup